



Innovative Cell and Tissue Technology

Press release
January 19, 2009
Gothenburg, Sweden

Vitrolife acquires further shares in A.T.S.

Vitrolife is acquiring a further 10 percent of the shares in A.T.S. Srl, the distributor of Vitrolife's products in Italy. Vitrolife thereby owns 70 percent of the company. "We are very pleased with how A.T.S has developed over the past year: the development of both sales and earnings has been stronger than planned" says Magnus Nilsson, Vitrolife's CEO.

In January 2008 Vitrolife acquired 51 percent of the shares in A.T.S. Srl, the distributor of Vitrolife's products in Italy since 1999. The acquisition is in line with Vitrolife's strategy to operate under its own management in key markets and increases the opportunities for A.T.S. to be more aggressive and be able to increase its market share in the Italian market.

In the agreement there was an option for Vitrolife to acquire a further 9 percent of the shares within 6 months and subsequently a further 10 percent within 12 months of the original acquisition date, that is a total of 70 percent. The first part of this option was utilized in the beginning of July 2008 and it is the second part of the option that has now been utilized. For the first nine months of 2008, the acquisition positively affected the consolidated sales figure by SEK 5.0 million, with good profitability.

The seller of the shares is Paolo Trabucchi, one of the founders and previously the sole owner of A.T.S.

Approximately 24,000 infertility treatments are performed in Italy per year and the number of fertility centers amounts to approximately 300. The potential market value for instruments and media amounts to SEK 40-50 million.

January 19, 2009
Gothenburg, Sweden

Magnus Nilsson
CEO

Queries should be addressed to:

Magnus Nilsson, CEO, phone +46 31 721 80 61
Anna Ahlberg, CFO, phone +46 31 721 80 13

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation.

The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body in order to select usable organs and keeping them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 140 employees and its products are sold in more than 80 markets. The company is headquartered in Gothenburg, Sweden, and there are subsidiaries in USA, Australia, France and Italy. Production facilities are located in Sweden and the USA.

The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com. Homepage: www.vitrolife.com.

The information in this press release is such as that which Vitrolife is required to publish in accordance with the Swedish Securities Market Act. The information was submitted for publication on 19 January 2009 at 08.00 CET.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.